Key result
Warfarin (target INR 2.0-3.0) reduces the risk of stroke by 68% (95% CI 50-79%) in patients with atrial fibrillation, while aspirin provides a 21% risk reduction.
Why the study?
Does antithrombotic therapy reduce the risk of stroke and thromboembolic events in patients with atrial fibrillation?
Does antithrombotic therapy reduce the risk of stroke and thromboembolic events in patients with atrial fibrillation?
Effect estimate: Risk reduction 68% (95% CI 50-79)
Risk stratification should be used to identify high-risk atrial fibrillation patients who would benefit from anticoagulation with warfarin over aspirin.
No takes yet. Share an insight, caveat, or question.
May support warfarin over aspirin in high-risk AF; leaves open optimal regimens versus NOACs.
Li-Saw-Hee et al. (1999) conducted a review in Atrial fibrillation. Warfarin was evaluated on Stroke (Risk reduction 68%, 95% CI 50-79). Warfarin (target INR 2.0-3.0) reduces the risk of stroke by 68% (95% CI 50-79%) in patients with atrial fibrillation, while aspirin provides a 21% risk reduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: